Abstract: There is disclosed a pharmaceutical composition comprising racemic aminopterin or pharmaceutically acceptable salts thereof. There is further disclosed a method to treat a disorder in a patient comprising administering a therapeutically effective amount of racemic aminopterin or pharmaceutically acceptable salts of racemic aminopterin. More particularly, there is disclosed a method for treating disorders modulated by at least dihydrofolate reductase activity, such as cancers and inflammatory disorders, wherein the method comprises administering to a patient in need thereof a therapeutically effective amount of racemic aminopterin or a pharmaceutically acceptable salt thereof.

Abstract: There is disclosed dosage forms and methods for treating a patient with an inflammatory disorder with a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof, that achieve efficacy without concomitant toxicity. Specifically, there is disclosed a method for treating an inflammatory disorder in a patient with uninterrupted doses of aminopterin.

Abstract: The present invention relates to pharmaceutical compositions containing the antifolate aminopterin, processes for making the compositions, and methods of using them to treat disorders in adult and pediatric patients. Pharmaceutical compositions substantially free of impurities are provided comprising a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof. Relative to the teachings of the prior art, the disclosed methods and compositions provide unexpected improvements that include a greater interpatient oral bioavailability in pediatric patients, a smaller interpatient coefficient of variation of oral bioavailability, a smaller mean intrapatient coefficient of variation of oral bioavailability, a greater therapeutic index, a smaller coefficient of variation of toxicity, efficacy in combination therapy, and efficacy of certain polyglutamated metabolites.

Abstract: There is disclosed a membrane formulation having high flux for forward osmosis applications. There is disclosed a forward osmosis filtration membrane having a salt rejection 99+% or greater, and comprising an asymmetric hydrophobic porous backing and cellulosic fibers. The membranes of the present invention find use in a variety of applications including osmotic-driven water purification and filtration, desalination of sea water, purification of contaminated aqueous waste streams, and the like. Specifically, there is disclosed a forward osmosis filtration membrane having a skin layer for salt rejection and a porous scaffold layer having a woven or non-woven mesh embedded within it.

Abstract: There is disclosed a process and device for Forward Osmosis (FO) Pressurized Device (FOPD) in general and one hydraulically coupled to a reverse osmosis (RO device for a FOPRO (Forward Osmosis Pressurized Reverse Osmosis). Specifically, there is disclosed a passive device (that is, not needed energy input) for using forward osmosis to generate significant hydraulic pressure that can be used to drive a reverse osmosis process, wherein the reverse osmosis process (not needed external energy to run pumps) can separate salt from salt water to generate potable water from water with high salt content (such as sea water, urine, sweat, brackish water and the like).

Abstract: There is disclosed a coating material formulation for layering a plurality of electrodes to provide a substrate for the electrochemical synthesis of organic oligomers. Specifically, there is disclosed a coating layer of from about 0.5 to about 100 microns thick and is composed of a mixture of controlled porosity glass (CPG) particles having an average particle size of from about 0.25 to about 25 microns, and a thickening agent.

Abstract: There is disclosed a spiral-wound membrane module design for various membrane filtration techniques having significantly reduced fluid flow resistance in the feed stream path. Specifically, the inventive spiral-wound membrane module is designed having a corrugated entrance and exit spacers together over less than 10% of the length of the spiral wound module and a stiffener sheet wound to provide for uniform feed channel gap width.

Abstract: There is disclosed a process and device for Forward Osmosis (FO) Pressurized Device (FOPD) in general and one hydraulically coupled to a reverse osmosis (RO device for a FOPRO (Forward Osmosis Pressurized Reverse Osmosis). Specifically, there is disclosed a passive device (that is, not needed energy input) for using forward osmosis to generate significant hydraulic pressure that can be used to drive a reverse osmosis process, wherein the reverse osmosis process (not needed external energy to run pumps) can separate salt from salt water to generate potable water from water with high salt content (such as sea water, urine, sweat, brackish water and the like).

Abstract: There is disclosed a process for melting a luminescent oxygen sensitive compound into extruded polymer films. Specifically, there is disclosed a process for thermal melting of oxygen-sensitive indicators into common packaging polymers used for commercial packaging of products, such as foods. The oxygen-sensitive indicators can be used for real-time monitoring of oxygen in commercial packaging operations.

Abstract: There is disclosed a spiral-wound membrane module design for various membrane filtration techniques having significantly reduced fluid flow resistance in the feed stream path. Specifically, the inventive spiral-wound membrane module is designed having a corrugated entrance and exit spacers together over less than 10% of the length of the spiral wound module and a stiffener sheet wound to provide for uniform feed channel gap width.

Abstract: There is disclosed amembrane assisted evaporation process (MAE) for economically and reliably removing water added to brine. The process comprises using low-grade waste heat and air to evaporate water from diluted salt brines when the water moves across a membrane in a liquid state.

Abstract: This invention concerns new methods and compositions that are useful in preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly, the invention relates to aromatic guanylhydrazone (more properly termed amidinohydrazone) compositions and their use to inhibit the uptake of arginine by macrophages and/or its conversion to urea. These compositions and methods are also useful in preventing the generation of nitric oxide (NO) by cells, and so to prevent NO-mediated inflammation and other responses in persons in need of same. In another embodiment, the compounds can be used to inhibit arginine uptake in arginine-dependent tumors and infections.

Abstract: This invention concerns new methods and compositions that are useful in preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly, the invention relates to aromatic guanylhydrazone (more properly termed amidinohydrazone) compositions and their use to inhibit the uptake of arginine by macrophages and/or its conversion to urea. These compositions and methods are also useful in preventing the generation of nitric oxide (NO) by cells, and so to prevent NO-mediated inflammation and other responses in persons in need of same. In another embodiment, the compounds can be used to inhibit arginine uptake in arginine-dependent tumors and infections.

Abstract: There is disclosed a method for treating diseases and disorders involving T cell activation and HIV-infection, using the p38 mitogen activated protein kinase (MAPK) signaling pathway as a target for intervention. There is further disclosed a use for guanylhydrazone-substituted compounds to treat diseases and disorders related to T cell activation and HIV-infection.

Abstract: The present invention relates to compositions and methods for inhibiting the release and/or biological activity of migration inhibitory factor (MIF). In particular, the invention relates to the uses of such compositions and methods for the treatment of various conditions involving cytokine-mediated toxicity, which include, but are not limited to shock, inflammation, graft versus host disease, and/or autoimmune diseases.

Abstract: This invention concerns new methods and compositions that are useful in preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly, the invention relates to aromatic guanylhydrazone (more properly termed amidinohydrazone) compositions and their use to inhibit the uptake of arginine by macrophages and/or its conversion to urea. These compositions and methods are also useful in preventing the generation of nitric oxide (NO) by cells, and so to prevent NO-mediated inflammation and other responses in persons in need of same. In another embodiment, the compounds can be used to inhibit arginine uptake in arginine-dependent tumors and infections.

Abstract: This invention concerns new methods and compositions that are useful in preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly, the invention relates to aromatic guanylhydrazone (more properly termed amidinohydrazone) compositions and their use to inhibit the uptake of arginine by macrophages and/or its conversion to urea. These compositions and methods are also useful in preventing the generation of nitric oxide (NO) by cells, and so to prevent NO-mediated inflammation and other responses in persons in need of same. In another embodiment, the compounds can be used to inhibit arginine uptake in arginine-dependent tumors and infections.

Abstract: There is disclosed a programmable analog or mixed analog/digital circuit. More particularly, this invention provides a circuit architecture that is flexible for a programmable electronic hardware device or for an analog circuit whose input and output signals are analog or multi-valued in nature, and primarily continuous in time. There is further disclosed a design for a current-mode integrator and sample-and-hold circuit, based upon Miller effect.

Abstract: There is disclosed an apparatus that provides an apparatus for continuously re-hydrating, cooking or blanching dried solid products. Specifically, the apparatus provides controlled high pressure and temperature to continuously re-hydrate, cook or blanch dried food products while maintaining food product integrity and quality.

Abstract: There are disclosed filters for tobacco combustion products that, when employed in conjunction with exposure to tobacco smoke, inhibit the accumulation of AGEs and AGE-like tobacco- and tobacco smoke-derived adducts in individuals exposed to tobacco smoke. There is further disclosed a use of ascorbic acid and derivatives thereof for the preparation of filters to inhibit the accumulation of advanced glycation endproducts (AGEs) and AGE-like tobacco- and tobacco smoke-derived adducts in individuals exposed to tobacco smoke.